- Home
- OKYO vs DTIL Comparison
OKYO vs DTIL Comparison
Compare OKYO & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- DTIL
- Stock Information
- Founded
- OKYO 2007
- DTIL 2006
- Country
- OKYO United Kingdom
- DTIL United States
- Employees
- OKYO N/A
- DTIL N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- DTIL Health Care
- Exchange
- OKYO Nasdaq
- DTIL Nasdaq
- Market Cap
- OKYO 97.8M
- DTIL 81.4M
- IPO Year
- OKYO 2022
- DTIL 2019
- Fundamental
- Price
- OKYO $2.22
- DTIL $5.21
- Analyst Decision
- OKYO Strong Buy
- DTIL Strong Buy
- Analyst Count
- OKYO 1
- DTIL 2
- Target Price
- OKYO $7.00
- DTIL $47.00
- AVG Volume (30 Days)
- OKYO 136.7K
- DTIL 231.7K
- Earning Date
- OKYO 07-18-2025
- DTIL 11-03-2025
- Dividend Yield
- OKYO N/A
- DTIL N/A
- EPS Growth
- OKYO N/A
- DTIL N/A
- EPS
- OKYO N/A
- DTIL N/A
- Revenue
- OKYO N/A
- DTIL $698,000.00
- Revenue This Year
- OKYO N/A
- DTIL N/A
- Revenue Next Year
- OKYO N/A
- DTIL $135.19
- P/E Ratio
- OKYO N/A
- DTIL N/A
- Revenue Growth
- OKYO N/A
- DTIL N/A
- 52 Week Low
- OKYO $0.90
- DTIL $3.61
- 52 Week High
- OKYO $3.35
- DTIL $8.82
- Technical
- Relative Strength Index (RSI)
- OKYO 42.84
- DTIL 32.71
- Support Level
- OKYO $2.33
- DTIL $5.67
- Resistance Level
- OKYO $2.93
- DTIL $6.46
- Average True Range (ATR)
- OKYO 0.22
- DTIL 0.61
- MACD
- OKYO -0.05
- DTIL -0.27
- Stochastic Oscillator
- OKYO 10.46
- DTIL 0.14
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.